Personalisierte Resektionsverfahren bei neuroendokrinen Neoplasien des Pankreas

Zusammenfassung

Neuroendokrine Neoplasien des Pankreas (pNEN) haben eine steigende Inzidenz und erhalten klinisch dadurch eine immer höhere Relevanz. Neben den hormonell inaktiven pNEN gibt es die hormonproduzierenden Tumoren, und sowohl die inaktiven als auch die aktiven pNEN können entweder sporadisch oder hereditär vorkommen. Die Behandlung orientiert sich an tumorassoziierten Faktoren, aber auch an individuellen patienteneigenen Gegebenheiten. Für die Behandlung sind individuelle maßgeschneiderte Konzepte notwendig, welche die jeweiligen Faktoren und Gegebenheiten berücksichtigen.

Abstract

Neuroendocrine neoplasia of the pancreas (pNEN) has an increasing incidence and is therefore becoming increasingly clinically relevant. In addition to hormonally inactive pNEN, there are hormone-producing tumours and both inactive and active pNEN can be either sporadic or hereditary. Treatment is not only based on tumour-associated factors, but also on the individual patient’s own circumstances. Treatment must be based on individual, tailor-made concepts that consider the respective factors and circumstances.

Schlüsselwörter

Neoplasie - neuroendokrine Neoplasie - Pankreaschirurgie

Keywords

neoplasia - neuroendocrine neoplasia - pancreatic surgery

• Literatur

• 1 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
• 2 Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E. et al. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology 2017; 104: 1-10
• 3 Lawrence B, Gustafsson BI, Chan A. et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1-18
• 4 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342
• 5 Ito T, Lee L, Hijioka M. et al. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan. J Hepatobiliary Pancreat Sci 2015; 22: 574-577
• 6 de Laat JM, Tham E, Pieterman CR. et al. Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors. Eur J Endocrinol 2012; 167: 181-187
• 7 Bosch F, Werner J, Angele MK. et al. Oligometastases of neuroendocrine tumors-extent of surgery. Chirurg 2018; 89: 516-522
• 8 Frilling A, Modlin IM, Kidd M. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15: e8-e21
• 9 Bartolini I, Bencini L, Risaliti M. et al. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018; 2018: 9647247
• 10 Falconi M, Eriksson B, Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171
• 11 Bosch F, Ilhan H, Pfahler V. et al. Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surg Nutr 2020; 9: 312-321
• 12 Partelli S, Ramage JK, Massironi S. et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) </= 2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne) 2020; 7: 598438
• 13 Howe JR, Merchant NB, Conrad C. et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020; 49: 1-33
• 14 Mintziras I, Keck T, Werner J. et al. Implementation of Current ENETS Guidelines for Surgery of Small (</= 2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry. World J Surg 2019; 43: 175-182
• 15 Tanaka M, Heckler M, Mihaljevic AL. et al. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021; 28: 1614-1624
• 16 Hashim YM, Trinkaus KM, Linehan DC. et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 2014; 259: 197-203
• 17 Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol 2013; 20: 2815-2821
• 18 Partelli S, Cirocchi R, Crippa S. et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg 2017; 104: 34-41
• 19 Sadot E, Reidy-Lagunes DL, Tang LH. et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Ann Surg Oncol 2016; 23: 1361-1370
• 20 Sallinen V, Le Large TY, Galeev S. et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors – a systematic review and meta-analysis. HPB (Oxford) 2017; 19: 310-320
• 21 Damen MDC, Westerweel PE, Levin MD. et al. Unmet supportive care needs, anxiety and depression in haematology patients during watch-and-wait. Psychooncology 2022; 31: 176-184
• 22 Partelli S, Andreasi V, Rancoita PMV. et al. Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. Surg Endosc 2021; 35: 165-173
• 23 Hackert T, Hinz U, Fritz S. et al. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg 2011; 396: 1197-1203
• 24 Jin JB, Qin K, Li H. et al. Robotic Enucleation for Benign or Borderline Tumours of the Pancreas: A Retrospective Analysis and Comparison from a High-Volume Centre in Asia. World J Surg 2016; 40: 3009-3020
• 25 Shirota T, Nagakawa Y, Sahara Y. et al. Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach. Gland Surg 2018; 7: 12-19
• 26 Giuliani T, Marchegiani G, Girgis MD. et al. Endoscopic placement of pancreatic stent for “Deep” pancreatic enucleations operative technique and preliminary experience at two high-volume centers. Surg Endosc 2020; 34: 2796-2802
• 27 Bosch F, Hofmann K, Coenen M. et al. Surgical treatment of pNET – Experience of a “high-volume” center. Surg Oncol 2018; 27: 409-414
• 28 Zhang XF, Lopez-Aguiar AG, Poultsides G. et al. Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. J Surg Oncol 2019; 120: 231-240
• 29 Scharf M, Petry V, Daniel H. et al. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance. Neuroendocrinology 2018; 106: 30-37
• 30 Nagtegaal ID, Odze RD, Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188
• 31 Yoshida T, Hijioka S, Hosoda W. et al. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol 2019; 26: 1385-1393
• 32 Merola E, Rinke A, Partelli S. et al. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Ann Surg Oncol 2020; 27: 1348-1355
• 33 Sorbye H, Welin S, Langer SW. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-160
• 34 Cho MS, Kasi A. Zollinger Ellison Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022
• 35 Belei OA, Heredea ER, Boeriu E. et al. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol 2017; 58: 371-376
• 36 Belfiori G, Wiese D, Partelli S. et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg 2018; 42: 3223-3230
• 37 Pavel M, O’Toole D, Costa F. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185
• 38 Norton JA, Fraker DL, Alexander HR. et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419
• 39 Fendrich V, Langer P, Waldmann J. et al. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 2007; 94: 1331-1341
• 40 Triponez F, Sadowski SM, Pattou F. et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small </= 2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Ann Surg 2018; 268: 158-164
• 41 Nell S, Verkooijen HM, Pieterman CRC. et al. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg 2018; 267: 1155-1160
• 42 Bartsch DK, Albers M, Knoop R. et al. Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. Neuroendocrinology 2013; 98: 290-298
• 43 Lopez CL, Falconi M, Waldmann J. et al. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg 2013; 257: 308-314